BR112017023261A2 - novos inibidores de epha4 que têm como alvo seus domínios de ligação ao ligante - Google Patents

novos inibidores de epha4 que têm como alvo seus domínios de ligação ao ligante

Info

Publication number
BR112017023261A2
BR112017023261A2 BR112017023261A BR112017023261A BR112017023261A2 BR 112017023261 A2 BR112017023261 A2 BR 112017023261A2 BR 112017023261 A BR112017023261 A BR 112017023261A BR 112017023261 A BR112017023261 A BR 112017023261A BR 112017023261 A2 BR112017023261 A2 BR 112017023261A2
Authority
BR
Brazil
Prior art keywords
target
new
ligand binding
binding domains
epha4 inhibitors
Prior art date
Application number
BR112017023261A
Other languages
English (en)
Inventor
Wu Bainan
Pellecchia Maurizio
De Surya
Original Assignee
Sanford Burnham Med Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Med Res Inst filed Critical Sanford Burnham Med Res Inst
Publication of BR112017023261A2 publication Critical patent/BR112017023261A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

são fornecidos no presente documento compostos e composições farmacêuticas compreendendo inibidores de epha4. os inibidores de epha4 e as composições dos mesmos são úteis para o tratamento de ela.
BR112017023261A 2015-04-29 2016-04-29 novos inibidores de epha4 que têm como alvo seus domínios de ligação ao ligante BR112017023261A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154670P 2015-04-29 2015-04-29
PCT/US2016/030070 WO2016176562A1 (en) 2015-04-29 2016-04-29 Novel epha4 inhibitors targeting its ligand binding domain

Publications (1)

Publication Number Publication Date
BR112017023261A2 true BR112017023261A2 (pt) 2018-08-07

Family

ID=57198786

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023261A BR112017023261A2 (pt) 2015-04-29 2016-04-29 novos inibidores de epha4 que têm como alvo seus domínios de ligação ao ligante

Country Status (10)

Country Link
US (1) US20180127464A1 (pt)
EP (1) EP3288932A4 (pt)
JP (1) JP2018519247A (pt)
KR (1) KR20170141730A (pt)
CN (1) CN107820495A (pt)
AU (1) AU2016255504A1 (pt)
BR (1) BR112017023261A2 (pt)
CA (1) CA2983277A1 (pt)
EA (1) EA201792380A1 (pt)
WO (1) WO2016176562A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110922349B (zh) * 2019-11-29 2022-04-26 四川大学 一种抗肿瘤化合物的合成及其在多发性骨髓瘤中的应用
JP2023522986A (ja) * 2020-04-23 2023-06-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｅｐｈａ４標的化合物及びその使用方法
US11732007B2 (en) 2020-09-28 2023-08-22 The Regents Of The University Of California Therapeutic compounds and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
KR20060034231A (ko) * 2003-06-06 2006-04-21 메디뮨 인코포레이티드 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도
RU2429246C2 (ru) * 2006-02-28 2011-09-20 Онкотерапи Сайенс, Инк. СПОСОБЫ РАЗРУШЕНИЯ КЛЕТОК С ИСПОЛЬЗОВАНИЕМ ЭФФЕКТОРНЫХ ФУНКЦИЙ АНТИ-EphA4 АНТИТЕЛ
US20100197688A1 (en) * 2008-05-29 2010-08-05 Nantermet Philippe G Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
WO2011021581A1 (ja) * 2009-08-20 2011-02-24 学校法人早稲田大学 標的生体高分子の選択的標識剤
EP2571487B1 (en) * 2010-05-21 2023-01-04 Siemens Healthcare Diagnostics Inc. Zwitterionic reagents
AU2011268256B8 (en) * 2010-06-16 2016-12-22 Mcgill University Growth hormone secretatogue receptor antagonists and uses thereof
FR3000494B1 (fr) * 2012-12-28 2015-08-21 Oribase Pharma Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases

Also Published As

Publication number Publication date
US20180127464A1 (en) 2018-05-10
EP3288932A1 (en) 2018-03-07
WO2016176562A1 (en) 2016-11-03
CN107820495A (zh) 2018-03-20
KR20170141730A (ko) 2017-12-26
EP3288932A4 (en) 2018-12-05
AU2016255504A1 (en) 2017-11-16
EA201792380A1 (ru) 2018-04-30
CA2983277A1 (en) 2016-11-03
JP2018519247A (ja) 2018-07-19

Similar Documents

Publication Publication Date Title
DK3616720T3 (da) Farmaceutisk sammensætning til cancerbehandling
PH12018500899A1 (en) Compositions and methods for inhibiting arginase activity
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
BR112018007021A2 (pt) compostos, composições e métodos para modulação de cftr
BR112017000672A2 (pt) composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
EA201691421A1 (ru) Гетероарилы и их применение
EA201690027A1 (ru) Ингибиторы ido
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
BR112018008103A2 (pt) análogos de celastrol
BR112017016465A2 (pt) composto heterocíclico e composição farmacêutica que o compreende
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
BR112017023225A2 (pt) inibidor de proteína cinase
DK3478284T3 (da) Forbindelser og sammensætninger til behandling af cancer
HK1244213A1 (zh) 預防或治療脂肪肝的藥物組合物
EA201791933A1 (ru) Ингибирование активности olig2
DK3240821T3 (da) Lavdosis gashydrathæmmersammensætning og tilhørende fremgangsmåde
BR112018005331A2 (pt) inibidores de pcna
EP3129378A4 (en) Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer
BR112017025724A2 (pt) grãos com teor reduzido de glúten e compostos dos mesmos
BR112017024163A2 (pt) compostos bicíclicos
BR112017023261A2 (pt) novos inibidores de epha4 que têm como alvo seus domínios de ligação ao ligante

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]